Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy

PD-1 and PD-L1 are crucial regulators of immunity expressed on the surface of T cells and tumour cells, respectively. Cancer cells frequently use PD-1/PD-L1 to evade immune detection; hence, blocking them exposes tumours to be attacked by activated T cells. The synergy of PD-1/PD-L1 blockade with ty...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Ali Razaghi, Mickaël Durand-Dubief, Nele Brusselaers, Mikael Björnstedt
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Subjects:	cancer interferon immunotherapy PD-1 PD-L1 interferon a (IFNa)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1249330/full